Assessing the Emergence of Resistance in vitro and Invivo: Linezolid Combined with Fosfomycin Against Fosfomycin-Sensitive and Resistant Enterococcus

References

• Starling S. Bacterial evolution: the origins of pathogenic enterococci. Nat Rev Microbiol. 2017;15(7):382–383. doi:10.1038/nrmicro.2017.65
   Web of Science ®Google Scholar
• Ch’ng JH, Chong KKL, Lam LN, et al. Biofilm-associated infection by enterococci. Nat Rev Microbiol. 2019;17(2):82–94. doi:10.1038/s41579-018-0107-z
   PubMed Web of Science ®Google Scholar
• Dahl A, Iversen K, Fosbol E, et al. Reply: Enterococcus faecalis infective endocarditis. J Am Coll Cardiol. 2019;74(19):2435–2436. doi:10.1016/j.jacc.2019.09.011
   Web of Science ®Google Scholar
• García-Solache M, Rice LB. The Enterococcus: a model of adaptability to its environment. Clin Microbiol Rev. 2019;32(2):e00058–18. doi:10.1128/CMR.00058-18
   PubMed Web of Science ®Google Scholar
• Gouliouris T, Coll F, Ludden C, et al. Quantifying acquisition and transmission of Enterococcus faecium using genomic surveillance. Nat Microbiol. 2021;6(1):103–111. doi:10.1038/s41564-020-00806-7
   PubMed Web of Science ®Google Scholar
• Arredondo-Alonso S, Top J, McNally A, et al. Plasmids shaped the recent emergence of the major nosocomial pathogen Enterococcus faecium. mBio. 2020;11(1):e03284–19. doi:10.1128/mBio.03284-19
   Web of Science ®Google Scholar
• Abbott IJ, Meletiadis J, Belghanch I, et al. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. J Antimicrob Chemother. 2018;73(3):709–719. doi:10.1093/jac/dkx441
   PubMed Web of Science ®Google Scholar
• Van Tyne D, Gilmore MS. Raising the alarmone: within-host evolution of antibiotic-tolerant. Enterococcus Faecium mBio. 2017;8(1):e00066–17.
   Google Scholar
• Chuang YC, Lin HY, Chen PY, et al. Survival of patients with vancomycin-resistant Enterococcus faecium bacteremia treated with conventional or high doses of daptomycin or linezolid is associated with the rate of bacterial clearance. Crit Care Med. 2018;46(10):1634–1642. doi:10.1097/CCM.0000000000003264
   Web of Science ®Google Scholar
• Schwartz MD, Shive DK, Shaikh ZH. Delayed discovery of linezolid-resistant, vancomycin-resistant Enterococcus faecium: lessons learned. Clin Infect Dis. 2004;38(1):155–156. doi:10.1086/380465
   Web of Science ®Google Scholar
• Yan Y, Yang G, Li Y, et al. Factorial design and post-antibiotic sub-MIC effects of linezolid combined with fosfomycin against vancomycin-resistant enterococci. Ann Transl Med. 2022;10(3):148. doi:10.21037/atm-21-4595
   Web of Science ®Google Scholar
• Qi C, Xu S, Wu M, et al. Pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and -resistant enterococci in vitro and in vivo of A Galleria mellonella larval infection model. Infect Drug Resist. 2019;12:3497–3505. doi:10.2147/IDR.S219117
   PubMed Web of Science ®Google Scholar
• Tao Y, Duma L, Rossez Y. Galleria mellonella as a good model to study Acinetobacter baumannii pathogenesis. Pathogens. 2021;10(11):1483. doi:10.3390/pathogens10111483
   Web of Science ®Google Scholar
• Piatek M, Sheehan G, Kavanagh K. Galleria mellonella: the versatile host for drug discovery, in vivo toxicity testing and characterising host-pathogen interactions. Antibiotics. 2021;10(12):1545. doi:10.3390/antibiotics10121545
   Web of Science ®Google Scholar
• Ménard G, Rouillon A, Cattoir V, et al. Galleria mellonella as a suitable model of bacterial infection: past, present and future. Front Cell Infect Microbiol. 2021;11:782733. doi:10.3389/fcimb.2021.782733
   PubMed Web of Science ®Google Scholar
• Li L, Chen H, Liu Y, et al. Synergistic effect of linezolid with fosfomycin against Staphylococcus aureus in vitro and in an experimental Galleria mellonella model. J Microbiol Immunol Infect. 2020;53(5):731–738. doi:10.1016/j.jmii.2018.12.007
   Google Scholar
• Ochoa S, Fernández F, Devotto L, et al. Virulence assessment of enterohepatic Helicobacter species carried by dogs using the wax moth larvae Galleria mellonella as infection model. Helicobacter. 2021;26(4):e12808. doi:10.1111/hel.12808
   Web of Science ®Google Scholar
• Yang HF, Pan AJ, Hu LF, et al. Galleria mellonella as an in vivo model for assessing the efficacy of antimicrobial agents against Enterobacter cloacae infection. J Microbiol Immunol Infect. 2017;50(1):55–61. doi:10.1016/j.jmii.2014.11.011
   Google Scholar
• Mao J, Li T, Zhang N, et al. Dose optimization of combined linezolid and fosfomycin against Enterococcus by using an in vitro pharmacokinetic/pharmacodynamic model. Microbiol Spectr. 2021;9(3):e0087121. doi:10.1128/Spectrum.00871-21
   Web of Science ®Google Scholar
• Melnyk AH, Wong A, Kassen R. The fitness costs of antibiotic resistance mutations. Evol Appl. 2015;8(3):273–283. doi:10.1111/eva.12196
   PubMed Web of Science ®Google Scholar
• Alame Emane AK, Guo X, Takiff HE, et al. Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis. Tuberculosis. 2021;129:102091. doi:10.1016/j.tube.2021.102091
   Web of Science ®Google Scholar
• Kempf I, Zeitouni S. Coût biologique de la résistance aux antibiotiques: analyse et conséquences [The cost of antibiotic resistance: analysis and consequences]. Pathol Biol. 2012;60(2):e9–e14. French. doi:10.1016/j.patbio.2009.10.013
   Google Scholar
• Li W, Liu Z, Yin W, et al. MCR expression conferring varied fitness costs on host bacteria and affecting bacteria virulence. Antibiotics. 2021;10(7):872. doi:10.3390/antibiotics10070872
   Web of Science ®Google Scholar
• Wang S, Liu H, Mao J, et al. Pharmacodynamics of linezolid plus fosfomycin against vancomycin-resistant Enterococcus faecium in a hollow fiber infection model. Front Microbiol. 2021;12:779885. doi:10.3389/fmicb.2021.779885
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 30th Informational supplement.CLSI M100-S30. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Davis H, Brown R, Ashcraft D, et al. In vitro synergy with fosfomycin plus doxycyclin against linezolid and vancomycin-resistant Enterococcus faecium. J Glob Antimicrob Resist. 2020;22:78–83. doi:10.1016/j.jgar.2020.01.014
   PubMed Web of Science ®Google Scholar
• Yang W, Liu J, Blažeković B, et al. In vitro antibacterial effects of Tanreqing injection combined with vancomycin or linezolid against methicillin-resistant Staphylococcus aureus. BMC Complement Altern Med. 2018;18(1):169. doi:10.1186/s12906-018-2231-8
   Web of Science ®Google Scholar
• Jemel S, Guillot J, Kallel K, et al. In vivo efficacy of voriconazole in a Galleria mellonella model of invasive infection due to azole-susceptible or resistant Aspergillus fumigatus isolates. J Fungi. 2021;7(12):1012. doi:10.3390/jof7121012
   Web of Science ®Google Scholar
• Xie N, Jiang L, Chen M, et al. In vitro and in vivo antibacterial activity of linezolid plus fosfomycin against Staphylococcus aureus with resistance to one drug. Infect Drug Resist. 2021;14:639–649. doi:10.2147/IDR.S290332
   Web of Science ®Google Scholar
• Billal DS, Fedorko DP, Yan SS, et al. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. J Antimicrob Chemother. 2007;59(1):28–34. doi:10.1093/jac/dkl428
   Web of Science ®Google Scholar
• Jiang L, Cai W, Tang F, et al. Characterization of fitness cost caused by tigecycline-resistance gene tet (X6) in different host bacteria. Antibiotics. 2021;10(10):1172. doi:10.3390/antibiotics10101172
   Web of Science ®Google Scholar
• Xia X, Yang L, Ling Y, et al. Emergence and mechanism of resistance of tulathromycin against Mycoplasma hyopneumoniae in a PK/PD model and the fitness costs of 23S rRNA mutants. Front Vet Sci. 2022;9:801800. doi:10.3389/fvets.2022.801800
   Web of Science ®Google Scholar
• Mališová L, Jakubů V, Pomorská K, et al. Spread of linezolid-resistant Enterococcus spp. in human clinical isolates in the Czech Republic. Antibiotics. 2021;10(2):219. doi:10.3390/antibiotics10020219
   Web of Science ®Google Scholar
• Dadashi M, Sharifian P, Bostanshirin N, et al. The global prevalence of daptomycin, tigecycline, and linezolid-resistant Enterococcus faecalis and Enterococcus faecium strains from human clinical samples: a systematic review and meta-analysis. Front Med. 2021;8:720647. doi:10.3389/fmed.2021.720647
   Web of Science ®Google Scholar
• Olearo F, Both A, Belmar Campos C, et al. Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption. Int J Med Microbiol. 2021;311(2):151477. doi:10.1016/j.ijmm.2021.151477
   PubMed Web of Science ®Google Scholar
• Smith TT, Tamma PD, Do TB, et al. Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium. Diagn Microbiol Infect Dis. 2018;91(2):161–163. doi:10.1016/j.diagmicrobio.2018.01.027
   PubMed Web of Science ®Google Scholar
• Egan SA, Shore AC, O’Connell B, et al. Linezolid resistance in Enterococcus faecium and Enterococcus faecalis from hospitalized patients in Ireland: high prevalence of the MDR genes optrA and poxtA in isolates with diverse genetic backgrounds. J Antimicrob Chemother. 2020;75(7):1704–1711. doi:10.1093/jac/dkaa075
   Web of Science ®Google Scholar
• Zhang Y, Dong G, Li J, et al. A high incidence and coexistence of multiresistance genes cfr and optrA among linezolid-resistant enterococci isolated from a teaching hospital in Wenzhou, China. Eur J Clin Microbiol Infect Dis. 2018;37(8):1441–1448. doi:10.1007/s10096-018-3269-8
   Web of Science ®Google Scholar
• Jiang L, Xie N, Chen M, et al. Synergistic combination of Linezolid and fosfomycin closing each other’s mutant selection window to prevent enterococcal resistance. Front Microbiol. 2021;11:605962. doi:10.3389/fmicb.2020.605962
   Web of Science ®Google Scholar
• Chai D, Liu X, Wang R, et al. Efficacy of Linezolid and fosfomycin in catheter-related biofilm infection caused by methicillin-resistant Staphylococcus aureus. Biomed Res Int. 2016;2016:6413982. doi:10.1155/2016/6413982
   PubMed Web of Science ®Google Scholar
• Falagas ME, Roussos N, Gkegkes ID, et al. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009;18(7):921–944. doi:10.1517/13543780902967624
   PubMed Web of Science ®Google Scholar
• Cai T, Tamanini I, Mattevi D, et al. Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: results of a pilot study. Int J Antimicrob Agents. 2020;56(1):105935. doi:10.1016/j.ijantimicag.2020.105935
   PubMed Web of Science ®Google Scholar
• Hemapanpairoa J, Changpradub D, Thunyaharn S, et al. Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect. Infect Drug Resist. 2019;12:2049–2057. doi:10.2147/IDR.S208298
   PubMed Web of Science ®Google Scholar
• Pan AJ, Mei Q, Ye Y, et al. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study. J Antibiot. 2017;70(2):166–173. doi:10.1038/ja.2016.124
   Web of Science ®Google Scholar
• Shen F, Tang X, Cheng W, et al. Fosfomycin enhances phagocyte-mediated killing of Staphylococcus aureus by extracellular traps and reactive oxygen species. Sci Rep. 2016;6:19262. doi:10.1038/srep19262
   PubMed Web of Science ®Google Scholar
• Thieme L, Hartung A, Makarewicz O, et al. In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model. J Antimicrob Chemother. 2020;75(8):2173–2181. doi:10.1093/jac/dkaa129
   Web of Science ®Google Scholar
• Killiny N. Generous hosts: why the larvae of greater wax moth, Galleria mellonella is a perfect infectious host model? Virulence. 2018;9(1):860–865. doi:10.1080/21505594.2018.1454172
   PubMed Web of Science ®Google Scholar
• Stanojević S, Blagojević V, Ćuruvija I, et al. Lactobacillus rhamnosus affects rat peritoneal cavity cell response to stimulation with gut microbiota: focus on the host innate immunity. Inflammation. 2021;44(6):2429–2447. doi:10.1007/s10753-021-01513-z
   Web of Science ®Google Scholar
• Trinh TD, Smith JR, Rybak MJ. Parenteral Fosfomycin for the treatment of multidrug resistant bacterial infections: the rise of the epoxide. Pharmacotherapy. 2019;39(11):1077–1094. doi:10.1002/phar.2326
   PubMed Web of Science ®Google Scholar
• Tsegka KG, Voulgaris GL, Kyriakidou M, et al. Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Rev Anti Infect Ther. 2022;20(1):33–43. doi:10.1080/14787210.2021.1932463
   PubMed Web of Science ®Google Scholar
• Guo Y, Tomich AD, McElheny CL, et al. High-level Fosfomycin resistance in vancomycin-resistant Enterococcus faecium. Emerg Infect Dis. 2017;23(11):1902–1904. doi:10.3201/eid2311.171130
   Web of Science ®Google Scholar
• Theophel K, Schacht VJ, Schlüter M, et al. The importance of growth kinetic analysis in determining bacterial susceptibility against antibiotics and silver nanoparticles. Front Microbiol. 2014;5:544. doi:10.3389/fmicb.2014.00544
   PubMed Web of Science ®Google Scholar
• Scortti M, Lacharme-Lora L, Wagner M, et al. Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox. Nat Med. 2006;12(5):515–517. doi:10.1038/nm1396
   Web of Science ®Google Scholar
• Scortti M, Han L, Alvarez S, et al. Epistatic control of intrinsic resistance by virulence genes in Listeria. PLoS Genet. 2018;14(9):e1007525. doi:10.1371/journal.pgen.1007525
   Web of Science ®Google Scholar
• Deng Y, Xu H, Su Y, et al. Horizontal gene transfer contributes to virulence and antibiotic resistance of Vibrio harveyi 345 based on complete genome sequence analysis. BMC Genomics. 2019;20(1):761. doi:10.1186/s12864-019-6137-8
   PubMed Web of Science ®Google Scholar
• Pourbaix A, Guérin F, Lastours V, et al. Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection. Int J Med Microbiol. 2017;307(8):452–459. doi:10.1016/j.ijmm.2017.09.019
   Web of Science ®Google Scholar
• Taglialegna A, Varela MC, Rosato RR, et al. VraSR and virulence trait modulation during daptomycin resistance in methicillin-resistant Staphylococcus aureus infection. mSphere. 2019;4(1):e00557–18. doi:10.1128/mSphere.00557-18
   Web of Science ®Google Scholar
• Parrett A, Reed JM, Gardner SG, et al. Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis. BMC Microbiol. 2020;20(1):162. doi:10.1186/s12866-020-01849-w
   Web of Science ®Google Scholar
• Marchi AP, Perdigão Neto LV, Martins RCR, et al. Vancomycin-resistant enterococci isolates colonizing and infecting haematology patients: clonality, and virulence and resistance profile. J Hosp Infect. 2018;99(3):346–355. doi:10.1016/j.jhin.2017.10.010
   Web of Science ®Google Scholar
• Nielsen KL, Pedersen TM, Udekwu KI, et al. Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic. J Antimicrob Chemother. 2012;67(6):1325–1332. doi:10.1093/jac/dks051
   Web of Science ®Google Scholar
• Yokoyama M, Stevens E, Laabei M, et al. Epistasis analysis uncovers hidden antibiotic resistance-associated fitness costs hampering the evolution of MRSA. Genome Biol. 2018;19(1):94. doi:10.1186/s13059-018-1469-2
   Web of Science ®Google Scholar
• Knight GM, Colijn C, Shrestha S, et al. The distribution of fitness costs of resistance-conferring mutations is a key determinant for the future burden of drug-resistant tuberculosis: a model-based analysis. Clin Infect Dis. 2015;61(Suppl 3):S147–S154. doi:10.1093/cid/civ579
   Web of Science ®Google Scholar
• Hubbard ATM, Jafari NV, Feasey N, et al. Effect of environment on the evolutionary trajectories and growth characteristics of antibiotic-resistant Escherichia coli mutants. Front Microbiol. 2019;10:2001. doi:10.3389/fmicb.2019.02001
   Web of Science ®Google Scholar
• Rasouly A, Shamovsky Y, Epshtein V, et al. Analysing the fitness cost of antibiotic resistance to identify targets for combination antimicrobials. Nat Microbiol. 2021;6(11):1410–1423. doi:10.1038/s41564-021-00973-1
   Web of Science ®Google Scholar
• El-Gaml RM, El-Khodary NM, Abozahra RR, et al. Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence. Eur J Clin Pharmacol. 2022;78(8):1301–1310. doi:10.1007/s00228-022-03340-z
   PubMed Web of Science ®Google Scholar
• La H, Bodolea C, Vlase L, et al. Linezolid administration to critically Ill patients: intermittent or continuous infusion? A systematic literature search and review. Antibiotics. 2022;11(4):436. doi:10.3390/antibiotics11040436
   Web of Science ®Google Scholar
• Zhu LL, Zhou Q. Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years. Infect Drug Resist. 2018;11:1105–1117. doi:10.2147/IDR.S167616
   PubMed Web of Science ®Google Scholar
• Boak LM, Li J, Rayner CR, et al. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother. 2007;51(4):1287–1292. doi:10.1128/AAC.01194-06
   PubMed Web of Science ®Google Scholar
• Lagatolla C, Milic J, Imperi F, et al. Synergistic activity of fosfomycin and chloramphenicol against vancomycin-resistant Enterococcus faecium (VREfm) isolates from bloodstream infections. Diagn Microbiol Infect Dis. 2021;99(2):115241. doi:10.1016/j.diagmicrobio.2020.115241
   Web of Science ®Google Scholar
• Liu BG, Yuan XL, He DD, et al. Research progress on the oxazolidinone drug linezolid resistance. Eur Rev Med Pharmacol Sci. 2020;24(18):9274–9281. doi:10.26355/eurrev_202009_23009
   Web of Science ®Google Scholar
• Katip W, Okonogi S, Oberdorfer P. The thirty-day mortality rate and nephrotoxicity associated with trough serum vancomycin concentrations during treatment of enterococcal infections: a propensity score matching analysis. Front Pharmacol. 2022;12:773994. doi:10.3389/fphar.2021.773994
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P, Monocentric Retrospective A. Study of AUC/MIC ratio of vancomycin associated with clinical outcomes and nephrotoxicity in patients with enterococcal infections. Pharmaceutics. 2021;13(9):1378. doi:10.3390/pharmaceutics13091378
   PubMed Web of Science ®Google Scholar
• Falagas ME, Athanasaki F, Voulgaris GL, et al. Resistance to fosfomycin: mechanisms, frequency and clinical consequences. Int J Antimicrob Agents. 2019;53(1):22–28. doi:10.1016/j.ijantimicag.2018.09.013
   PubMed Web of Science ®Google Scholar